丹参、川芎嗪对纤维蛋白溶解系统作用的初步研究

本实验观察丹参、川芎嗪两药在体内外对纤溶系统的作用,发现川芎嗪在体外具有尿激酶样作用,丹参静点后可提高冠心病患者纤溶酶原激活物水平,提示不同活血化瘀药物对纤溶系统作用的方式可能不同。     

FIBRINOLYTIC ACTIVITY IN CORONARY HEART DISEASE

To evaluate the effects of the fibrinolytic system on the development of coronary heart disease (CHD), the level of released plasminogen activator was measured by venous occlusion in 60 CHD cases, and 20 healthy subjects. The level of plasma basic plasminogen activator activity, plasminogen, fibrinogen and serum fibrin degradation products (FDP) were determined also. In comparison with control subjects, a lower level of released plasminogen activator was found in all CHD patients, being especially marked in those with unstable angina pectoris and acute myocardial infarction. The levels of plasma plasminogen, fibrinogen and FDP were also significantly changed in these patients. In acute myocardial infarction patients, the level of released plasminogen activator was lower in cases complicated with heart failure than in those without.     

组织型纤维蛋白溶酶原激活剂与急性心肌梗塞的溶栓治疗

冠状动脉内血栓形成在急性心肌梗塞的发病中占重要地位,约70～90%的急性透壁性心肌梗塞患者发病后在早期有冠状动脉内血栓堵塞。针对这一发病机制所采用的溶栓疗法在挽救濒死心肌、缩小梗塞范围、改善心脏功能方面已取得了良好效果。但常用的溶栓药物链激酶和尿激酶对循环血液的纤溶系统有全面激活作用,易引起“纤溶状态”(fibrilytic state),导致严重的出血并发症,故临床应用受到一定限制。具有血栓选择性作用的组织型纤维蛋白溶酶原激活